Big cohort metabolomic profiling of serum for oral squamous cell carcinoma screening and diagnosis
Natural Sciences · 2022-01 · 2 (1)
DOI: 10.1002/ntls.20210071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Natural Sciences, online erschienen am 15.11.2021. Verfasst von Xihu Yang und 12 weiteren Autor:innen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanjing Medical Science and Technique Development Foundation.
Abstract (Originalsprache)
The survival rate of oral squamous cell carcinoma (OSCC) can be greatly improved if intervention could be initiated as early as possible. This poses a technical demand for developing a sensitive screening and specific in vitro diagnosis method for OSCC. Herewith, a large cohort consisting of 241 healthy contrast (HC) and 578 OSCC patients were recruited for conducting the rapid metabolic profiling of trace volume serum using conductive polymer spray ionization mass spectrometry (CPSI‐MS). Statistical analysis picked out 65 metabolite ions as potential characteristic markers for differentiating OSCC from HC. With the aid of a supporting vector machine (SVM), OSCC can be distinguished from HC with an accuracy of 98.0% by cross‐validation in the discovery cohort and 89.6% accuracy in the validation cohort. Furthermore, orthogonal partial least square‐discriminant analysis (OPLS‐DA) also initially showed the potential for OSCC staging, especially between T1/T2 and T3/T4 stages with an accuracy of 90.1%. CPSI‐MS combined with SVM or OPLS‐DA can not only quickly distinguish OSCC from HC but also predict the OSCC progression from T1/2 to T3/4 stages in a few minutes, making it a promising tool for both screening and diagnosing high‐risk population. Key points Sixty‐five characteristic metabolite ions significantly changed in OSCC serum metabolic profile compared to that in the HC group. CPSI‐MS combined with SVM achieved 89.6% accuracy on the validation cohort for OSCC prediction. CPSI‐MS/OPLS‐DA can distinguish T1/T2 from T3/T4 stages with an accuracy of 90.1% by cross‐validation.
Förderung
- Nanjing Medical Science and Technique Development Foundation
Zitieren
APA
Yang, X., Song, X., Yang, X., Han, W., Fu, Y., Wang, S., Zhang, X., Sun, G., Lu, Y., Wang, Z., Ni, Y., Zare, R. N., & Hu, Q. (2022). Big cohort metabolomic profiling of serum for oral squamous cell carcinoma screening and diagnosis. Natural Sciences, 2(1). https://doi.org/10.1002/ntls.20210071
Vancouver
Yang X, Song X, Yang X, Han W, Fu Y, Wang S, et al. Big cohort metabolomic profiling of serum for oral squamous cell carcinoma screening and diagnosis. Natural Sciences. 2022;2(1). doi:10.1002/ntls.20210071
BibTeX
@article{Yang2022,
author = {Yang, Xihu and Song, Xiaowei and Yang, Xudong and Han, Wei and Fu, Yong and Wang, Shuai and Zhang, Xiaoxin and Sun, Guowen and Lu, Yong and Wang, Zhiyong and Ni, Yanhong and Zare, Richard N. and Hu, Qingang},
title = {Big cohort metabolomic profiling of serum for oral squamous cell carcinoma screening and diagnosis},
journal = {Natural Sciences},
year = {2022},
volume = {2},
number = {1},
doi = {10.1002/ntls.20210071}
}
EUVIMED